Our approach is simple:
1. Low Cost
2. Low Risk
3. Fast Market Entry
At the centre of our offering is a development process which synthesises the core drivers of generic and proprietary pharmaceutical models. Like generic companies, we base our products on known active ingredients used in proven diseases. Also like generics, our costs are kept extremely low.
The difference between Small Pharma and a classic generic model is that our products are clinically differentiated and defensible. We know how to generate effective IP from low cost development programmes. This allows us to protect our commercial interests and still deliver value to our patients.